Form 4 for KLRS Kalaris Therapeutics, Inc.
Accepted 2024-07-03 00:00:00 ET · period of report 2024-07-02 · accession 0000950170-24-081518 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-07-03 | 2024-07-02 | KLRS | Sinha Vikas | See Remarks, Dir, 10% | S - Sale | $0.72 | -939 | 1.17M | -0.1% | -$676.08 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-07-02 | S | D | 939 | $0.72 | 1,165,394 | D | — | — | (F2) Includes 36,337 shares acquired under the Allovir, Inc. 2020 Employee Stock Purchase Plan on June 28, 2024. |